A detailed history of Walleye Capital LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 9,976 shares of KYMR stock, worth $405,624. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,976
Holding current value
$405,624
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.16 - $52.4 $300,876 - $522,742
9,976 New
9,976 $472,000
Q1 2023

May 15, 2023

SELL
$24.84 - $38.75 $914,211 - $1.43 Million
-36,804 Reduced 70.33%
15,524 $459,000
Q4 2022

Feb 14, 2023

BUY
$19.57 - $30.92 $1.02 Million - $1.62 Million
52,328 New
52,328 $1.31 Million
Q2 2021

Aug 16, 2021

SELL
$31.08 - $51.95 $204,351 - $341,571
-6,575 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$35.64 - $85.46 $234,333 - $561,899
6,575 New
6,575 $256,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.22B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.